Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NRG Oncology
University of Chicago
Samsung Medical Center
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
University of Arizona
Dartmouth-Hitchcock Medical Center
University College, London
Case Comprehensive Cancer Center